[
  {
    "ts": null,
    "headline": "BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View",
    "summary": "Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.",
    "url": "https://finnhub.io/api/news?id=df14edfb5fb3dc2170010a255b7b393e3158b7516503e30dc6635dbcb1731837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770395400,
      "headline": "BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View",
      "id": 138378395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.",
      "url": "https://finnhub.io/api/news?id=df14edfb5fb3dc2170010a255b7b393e3158b7516503e30dc6635dbcb1731837"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Forecasts 2026 Profit Above Estimates as Shares Climb 30%",
    "summary": "Cost cuts support earnings outlook despite expected 2026 sales decline from multiple sclerosis competition.",
    "url": "https://finnhub.io/api/news?id=e8a422e7aa791c24ded6881d32ef23355bcc82852354a0f5721b0f8ca7b6df4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770394527,
      "headline": "Biogen Forecasts 2026 Profit Above Estimates as Shares Climb 30%",
      "id": 138377041,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Cost cuts support earnings outlook despite expected 2026 sales decline from multiple sclerosis competition.",
      "url": "https://finnhub.io/api/news?id=e8a422e7aa791c24ded6881d32ef23355bcc82852354a0f5721b0f8ca7b6df4e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB) Q4 2025 Earnings Call Transcript",
    "summary": "At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Full Year 2025 Earnings Call and Business Update.  During this call, we will make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements.",
    "url": "https://finnhub.io/api/news?id=8602f2bc74346eb371bfaf11adf76dbf9117b716b2a054a16a35d992fb8c93c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770391741,
      "headline": "Biogen (BIIB) Q4 2025 Earnings Call Transcript",
      "id": 138375629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Full Year 2025 Earnings Call and Business Update.  During this call, we will make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements.",
      "url": "https://finnhub.io/api/news?id=8602f2bc74346eb371bfaf11adf76dbf9117b716b2a054a16a35d992fb8c93c6"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Q4 Earnings Call Highlights",
    "summary": "Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to continued momentum in newer products and a late-stage pipeline that has expanded significantly over the past year. Management also laid out 2026 expectations, including a mid-singl",
    "url": "https://finnhub.io/api/news?id=2ffe67124a431f244033d631c7612c5b558a9f51b7f4f59efc453ebf0a663d6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770390656,
      "headline": "Biogen Q4 Earnings Call Highlights",
      "id": 138375630,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to continued momentum in newer products and a late-stage pipeline that has expanded significantly over the past year. Management also laid out 2026 expectations, including a mid-singl",
      "url": "https://finnhub.io/api/news?id=2ffe67124a431f244033d631c7612c5b558a9f51b7f4f59efc453ebf0a663d6e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=468e45fb6c9596af32e6e6252fe2c900b0634e582bbd80f8659167992bc74072",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770388205,
      "headline": "Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 138377042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=468e45fb6c9596af32e6e6252fe2c900b0634e582bbd80f8659167992bc74072"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript",
    "summary": "Biogen Inc. (BIIB) Q4 2025 Earnings Call February 6, 2026 8:30 AM ESTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
    "url": "https://finnhub.io/api/news?id=7134d9e9fb33b3a0010c3e0b09c20bc765e2d9640d389b1a9edfdb54251a0a09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770387263,
      "headline": "Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript",
      "id": 138377839,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen Inc. (BIIB) Q4 2025 Earnings Call February 6, 2026 8:30 AM ESTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
      "url": "https://finnhub.io/api/news?id=7134d9e9fb33b3a0010c3e0b09c20bc765e2d9640d389b1a9edfdb54251a0a09"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Revenue Down as Multiple Sclerosis Sales Slide",
    "summary": "Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.",
    "url": "https://finnhub.io/api/news?id=3f23bdd8a798aa304f3513feb245ae5b8a4a750e053908cba4d8beadaada170e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770386340,
      "headline": "Biogen Revenue Down as Multiple Sclerosis Sales Slide",
      "id": 138377043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.",
      "url": "https://finnhub.io/api/news?id=3f23bdd8a798aa304f3513feb245ae5b8a4a750e053908cba4d8beadaada170e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide",
    "summary": "Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.",
    "url": "https://finnhub.io/api/news?id=41a7857afd2a5304ca566f26f839682b4fee36e9b73d7ab2e53e763610d37adb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770386340,
      "headline": "Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide",
      "id": 138375631,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.",
      "url": "https://finnhub.io/api/news?id=41a7857afd2a5304ca566f26f839682b4fee36e9b73d7ab2e53e763610d37adb"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Rises, Bitcoin Bounces; Amazon Dives On Earnings (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rebounded Friday as the price of bitcoin bounced. Amazon stock dived on earnings.",
    "url": "https://finnhub.io/api/news?id=fb90cc0a6c3fdc620c3b4eeec3e9ee40302687830387a110e37ef2895d0e5e1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770385524,
      "headline": "Stock Market Today: Dow Rises, Bitcoin Bounces; Amazon Dives On Earnings (Live Coverage)",
      "id": 138374306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rebounded Friday as the price of bitcoin bounced. Amazon stock dived on earnings.",
      "url": "https://finnhub.io/api/news?id=fb90cc0a6c3fdc620c3b4eeec3e9ee40302687830387a110e37ef2895d0e5e1d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.",
    "summary": "Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.",
    "url": "https://finnhub.io/api/news?id=b333ab0a1768a7c0b038f5a2025627fbe7007ba878dd3d68bf1de6c88555bea2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770381300,
      "headline": "Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.",
      "id": 138374484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.",
      "url": "https://finnhub.io/api/news?id=b333ab0a1768a7c0b038f5a2025627fbe7007ba878dd3d68bf1de6c88555bea2"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Gain Pre-Bell as Wall Street Eyes Recovery After Selloff",
    "summary": "The benchmark US stock measures were trending higher before the open Friday as markets looked to end",
    "url": "https://finnhub.io/api/news?id=0ed0433de1d4b9711c35be0507f50f52295de64bf110c34c168126de4599ce3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770380542,
      "headline": "Stocks Gain Pre-Bell as Wall Street Eyes Recovery After Selloff",
      "id": 138374346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The benchmark US stock measures were trending higher before the open Friday as markets looked to end",
      "url": "https://finnhub.io/api/news?id=0ed0433de1d4b9711c35be0507f50f52295de64bf110c34c168126de4599ce3c"
    }
  },
  {
    "ts": null,
    "headline": "Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results topping the market’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=4ec47393a5a5a5444b0321e2fde6855e3fcc91fe96c23d46f520afe5b2915e8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770380223,
      "headline": "Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales",
      "id": 138374601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results topping the market’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=4ec47393a5a5a5444b0321e2fde6855e3fcc91fe96c23d46f520afe5b2915e8b"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates",
    "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +23.40% and +3.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=0f1ebf4e36332c9f57c7ba9f3597e63d1f65dbf0ba01eb00b0ea4217d91e3be4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770380102,
      "headline": "Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates",
      "id": 138375632,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +23.40% and +3.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=0f1ebf4e36332c9f57c7ba9f3597e63d1f65dbf0ba01eb00b0ea4217d91e3be4"
    }
  },
  {
    "ts": null,
    "headline": "Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong",
    "summary": "Investing.com -- Biogen Inc. (NASDAQ:BIIB) reported better-than-expected fourth quarter 2025 results on Thursday, with adjusted earnings and revenue surpassing analyst estimates, while also providing an optimistic outlook for 2026.",
    "url": "https://finnhub.io/api/news?id=1592dd319c70d7fa1d88103fa865a41373fea73e15f3577fef09d91358f70668",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770379400,
      "headline": "Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong",
      "id": 138374602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com -- Biogen Inc. (NASDAQ:BIIB) reported better-than-expected fourth quarter 2025 results on Thursday, with adjusted earnings and revenue surpassing analyst estimates, while also providing an optimistic outlook for 2026.",
      "url": "https://finnhub.io/api/news?id=1592dd319c70d7fa1d88103fa865a41373fea73e15f3577fef09d91358f70668"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. 2025 Q4 - Results - Earnings Call Presentation",
    "summary": "2026-02-06. The following slide deck was published by Biogen Inc.",
    "url": "https://finnhub.io/api/news?id=387ae26eb8f10ce63ae8791ceba19e24647312e93c3a7901eb4fa299c23500f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770377528,
      "headline": "Biogen Inc. 2025 Q4 - Results - Earnings Call Presentation",
      "id": 138375912,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "2026-02-06. The following slide deck was published by Biogen Inc.",
      "url": "https://finnhub.io/api/news?id=387ae26eb8f10ce63ae8791ceba19e24647312e93c3a7901eb4fa299c23500f8"
    }
  },
  {
    "ts": null,
    "headline": "Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025",
    "summary": "BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 127 million, which is an increase of approximately 31 percent compared to the royalty obtained by BioArctic for the fourth quarter 2024.",
    "url": "https://finnhub.io/api/news?id=86c8554243e7ab5c86d658720ec33bc7698efd0c1db73c4f015e5f71b4c47aa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770376980,
      "headline": "Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025",
      "id": 138373699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 127 million, which is an increase of approximately 31 percent compared to the royalty obtained by BioArctic for the fourth quarter 2024.",
      "url": "https://finnhub.io/api/news?id=86c8554243e7ab5c86d658720ec33bc7698efd0c1db73c4f015e5f71b4c47aa5"
    }
  },
  {
    "ts": null,
    "headline": "Biogen forecasts annual profit above estimates as Leqembi sales pick up",
    "summary": "Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's treatment Leqembi as older multiple sclerosis drugs",
    "url": "https://finnhub.io/api/news?id=c17215bd5f578d680582dd0a66bbdc3efea2d2ece2caf48a6ca8b8d33a5a7f2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770376454,
      "headline": "Biogen forecasts annual profit above estimates as Leqembi sales pick up",
      "id": 138373700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's treatment Leqembi as older multiple sclerosis drugs",
      "url": "https://finnhub.io/api/news?id=c17215bd5f578d680582dd0a66bbdc3efea2d2ece2caf48a6ca8b8d33a5a7f2f"
    }
  },
  {
    "ts": null,
    "headline": "How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat",
    "summary": "Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment Tysabri.",
    "url": "https://finnhub.io/api/news?id=efd2a29ddba423345022222a2a0932214ee8091e100b24cee385be398020b05f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770375952,
      "headline": "How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat",
      "id": 138373701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment Tysabri.",
      "url": "https://finnhub.io/api/news?id=efd2a29ddba423345022222a2a0932214ee8091e100b24cee385be398020b05f"
    }
  },
  {
    "ts": null,
    "headline": "Consumer Sentiment, Biogen Earnings: What to Watch Friday",
    "summary": "Friday's jobs report was postponed by the brief government shutdown, but there are a couple of other data releases on the docket, plus a few more earnings reports to round out a big week for corporate results.",
    "url": "https://finnhub.io/api/news?id=474e20e94986cc11045272781df113fcef9d33f53d1b8e231cf9a666b6a5932c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770374357,
      "headline": "Consumer Sentiment, Biogen Earnings: What to Watch Friday",
      "id": 138373587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Friday's jobs report was postponed by the brief government shutdown, but there are a couple of other data releases on the docket, plus a few more earnings reports to round out a big week for corporate results.",
      "url": "https://finnhub.io/api/news?id=474e20e94986cc11045272781df113fcef9d33f53d1b8e231cf9a666b6a5932c"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Friday: Amazon, Roblox, Stellantis, Strategy",
    "summary": "↘️ Amazon (AMZN): The online retailer and cloud-computing company plans $200 billion in capital spending this year, as it ramps up investment in artificial intelligence. Shares sank 7% premarket. ↘️ Stellantis (IT:STLAM), (STLA): The Jeep maker will book charges of about $26 billion as it scales back a push into electric vehicles.",
    "url": "https://finnhub.io/api/news?id=30ddfb83b144f002f222a1c7f911d1b0fabfe28d6bd1512dd0c7799ab6c03716",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770374105,
      "headline": "Stocks to Watch Friday: Amazon, Roblox, Stellantis, Strategy",
      "id": 138373529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "↘️ Amazon (AMZN): The online retailer and cloud-computing company plans $200 billion in capital spending this year, as it ramps up investment in artificial intelligence. Shares sank 7% premarket. ↘️ Stellantis (IT:STLAM), (STLA): The Jeep maker will book charges of about $26 billion as it scales back a push into electric vehicles.",
      "url": "https://finnhub.io/api/news?id=30ddfb83b144f002f222a1c7f911d1b0fabfe28d6bd1512dd0c7799ab6c03716"
    }
  },
  {
    "ts": null,
    "headline": "Under Armour earnings, Fed, Liftoff Mobile IPO: What to Watch",
    "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Friday, February 6, including earnings results from Under Armour (UAA, UA), Biogen (BIIB), and Philip Morris (PM); commentary from Federal Reserve Vice Chair Philip Jefferson; and Liftoff Mobile making its public debut on the Nasdaq, trading under the ticker LFTO. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=d77cba8344e4c1b3ced138076baca7b178bf8be3f8706ec26c89e0c31dca578a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770336021,
      "headline": "Under Armour earnings, Fed, Liftoff Mobile IPO: What to Watch",
      "id": 138369902,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Friday, February 6, including earnings results from Under Armour (UAA, UA), Biogen (BIIB), and Philip Morris (PM); commentary from Federal Reserve Vice Chair Philip Jefferson; and Liftoff Mobile making its public debut on the Nasdaq, trading under the ticker LFTO. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=d77cba8344e4c1b3ced138076baca7b178bf8be3f8706ec26c89e0c31dca578a"
    }
  }
]